Keyphrases
Cardiovascular Risk
100%
Cyclooxygenase-2 Inhibitors
100%
COX-2 Inhibitors
100%
Cyclooxygenase-2
75%
Meta-analysis
50%
Prostacyclin
50%
Endothelial Function
50%
Rofecoxib
50%
Celecoxib
50%
Class Effect
50%
Thromboxane A2 (TXA2)
50%
Inflammation
25%
Clinical Trials
25%
Acute Coronary Syndrome
25%
Randomized Controlled Trial
25%
Aspirin
25%
Low-dose Aspirin
25%
Clinical Outcomes
25%
C-reactive Protein
25%
Platelets
25%
Platelet Inhibition
25%
Platelet Aggregation
25%
Homeostasis
25%
LDL Cholesterol
25%
Published Data
25%
Prothrombotic State
25%
Vasodilation
25%
Endothelium-dependent Vasodilation
25%
Vasoconstriction
25%
Cardiovascular Effects
25%
Cyclooxygenase-1 (COX-1)
25%
Vioxx
25%
Meloxicam
25%
Trial Publication
25%
Low-dose Heparin
25%
Celebrex
25%
Relative Selectivity
25%
Pharmacology, Toxicology and Pharmaceutical Science
Cardiovascular Risk
100%
COX-2 Inhibitor
100%
Rofecoxib
60%
Celecoxib
60%
Observational Study
40%
Acetylsalicylic Acid
40%
Prostacyclin
40%
Thromboxane A2
40%
Inflammation
20%
Acute Coronary Syndrome
20%
Randomized Controlled Trial
20%
Case-Control Study
20%
Clinical Trial
20%
C Reactive Protein
20%
Heparin
20%
Low Density Lipoprotein Cholesterol
20%
APC
20%
Cyclooxygenase 1
20%
Meloxicam
20%
Biochemistry, Genetics and Molecular Biology
COX-2 Inhibitor
100%
Celecoxib
60%
Rofecoxib
60%
Observational Study
40%
Prostacyclin
40%
Vasodilatation
40%
Platelet
40%
Thromboxane A2
40%
Low Drug Dose
20%
Homeostasis
20%
Clinical Trial
20%
Case-Control Study
20%
Thrombocyte Aggregation
20%
Heparin
20%
Cyclooxygenase
20%
Randomized Controlled Trial
20%
C-Reactive Protein
20%
Vasoconstriction
20%
Cardiovascular Effect
20%
Meloxicam
20%